Article Text
Oral Presentations – Monday, September 26, 2005
00014 A PHASE II STUDY OF THE AGO OVARIAN CANCER STUDY GROUP (AGO-OVAR 2.6): ZD1839 IN COMBINATION WITH TAMOXIFEN IN REFRACTORY OVARIAN CANCER
Statistics from Altmetric.com
This is a PDF-only article. The first page of the PDF of this article appears above.